Population pharmacokinetic modelling of recombinant factor IX Fc fusion protein (rFIXFc) in patients with haemophilia B

Clinical Pharmacokinetics

Volumn 53, Issue 5, 2014, Pages 467-477

  Diao, Lei ^a   Li, Shuanglian ^a   Ludden, Thomas ^b   Gobburu, Jogarao ^c   Nestorov, Ivan ^a   Jiang, Haiyan ^a  

^a BIOGEN   (United States)

^b Department of Pharmacy Practice and Science School of Pharmacy University of Maryland ^*  (United States)

^c UNIVERSITY OF MARYLAND SCHOOL OF PHARMACY   (United States)

Author keywords

[No Author keywords available]

Indexed keywords

BLOOD CLOTTING FACTOR; HYBRID PROTEIN; RECOMBINANT BLOOD CLOTTING FACTOR 9; RECOMBINANT FACTOR IX FC FUSION PROTEIN; UNCLASSIFIED DRUG; BLOOD CLOTTING FACTOR 9; IMMUNOGLOBULIN FC FRAGMENT;

ADOLESCENT; ADULT; AGED; ARTICLE; BODY WEIGHT; CHILD; COMPARTMENT MODEL; COMPUTER PROGRAM; CONTROLLED STUDY; DRUG CLEARANCE; DRUG DISTRIBUTION; HEMOPHILIA B; HUMAN; LIMIT OF QUANTITATION; MAJOR CLINICAL STUDY; PARTIAL THROMBOPLASTIN TIME; PHASE 1 CLINICAL TRIAL (TOPIC); PHASE 2 CLINICAL TRIAL (TOPIC); PHASE 3 CLINICAL TRIAL (TOPIC); PRIORITY JOURNAL; STEADY STATE; SUBSTITUTION THERAPY; THREE COMPARTMENT MODEL; BIOLOGICAL MODEL; BLOOD; CLINICAL TRIAL; METABOLISM; MIDDLE AGED; PHASE 1 CLINICAL TRIAL; PHASE 2 CLINICAL TRIAL; PHASE 3 CLINICAL TRIAL; YOUNG ADULT;

ADOLESCENT; ADULT; AGED; CHILD; FACTOR IX; HEMOPHILIA B; HUMANS; IMMUNOGLOBULIN FC FRAGMENTS; MIDDLE AGED; MODELS, BIOLOGICAL; RECOMBINANT FUSION PROTEINS; YOUNG ADULT;

EID: 84900840847     PISSN: 03125963     EISSN: 11791926     Source Type: Journal    
DOI: 10.1007/s40262-013-0129-7     Document Type: Article

References (29)

1. Mannucci PM, Tuddenham EG. The hemophilias - from royal genes to gene therapy. N Engl J Med. 2001;344(23):1773-9.
2. Giangrande P. Haemophilia B: Christmas disease. Expert Opin Pharmacother. 2005;6(9):1517-24.
3. Srivastava A, Brewer AK, Mauser-Bunschoten EP, Key NS, Kitchen S, Llinas A, et al. Guidelines for the management of hemophilia. Haemophilia. 2013;19(1):e1-47.
4. Roopenian DC, Akilesh S. FcRn: the neonatal Fc receptor comes of age. Nat Rev Immunol. 2007;7(9):715-25.
5. Kuo TT, Aveson VG. Neonatal Fc receptor and IgG-based therapeutics. MAbs. 2011;3(5):422-30.
6. Shapiro AD, Ragni MV, Valentino LA, Key NS, Josephson NC, Powell JS, et al. Recombinant factor IX-Fc fusion protein (rFIXFc) demonstrates safety and prolonged activity in a phase 1/2a study in hemophilia B patients. Blood. 2012;119(3):666-72.
7. Peters RT, Low SC, Kamphaus GD, Dumont JA, Amari JV, Lu Q, et al. Prolonged activity of factor IX as a monomeric Fc fusion protein. Blood. 2010;115(10):2057-64.
8. Powell JS, Pasi J, Ragni MV, Ozelo MC, Valentino LA, Mahlangu JN, et al. Study of recombinant factor IX Fc fusion protein in hemophilia B. N Engl J Med. 2013;369:2313-23.
9. Beal SL. Ways to fit a PK model with some data below the quantification limit. J Pharmacokinet Pharmacodyn. 2001;28(5):481-504.
10. Byon W, Smith MK, Chan P, Tortorici MA, Riley S, Dai H, et al. Establishing best practices and guidance in population modeling: an experience with an internal population pharmacokinetic analysis guidance. CPT Pharmacometrics Syst Pharmacol. 2013;2:e51.
11. Bergstrand M, Karlsson MO. Handling data below the limit of quantification in mixed effect models. AAPS J. 2009;11(2):371-80.
12. Bjorkman S, Ahlen V. Population pharmacokinetics of plasma-derived factor IX in adult patients with haemophilia B: implications for dosing in prophylaxis. Eur J Clin Pharmacol. 2012;68(6):969-77.
13. Bjorkman S, Carlsson M, Berntorp E. Pharmacokinetics of factor IX in patients with haemophilia B. Methodological aspects and physiological interpretation. Eur J Clin Pharmacol. 1994;46(4):325-32.
14. Bjorkman S, Shapiro AD, Berntorp E. Pharmacokinetics of recombinant factor IX in relation to age of the patient: implications for dosing in prophylaxis. Haemophilia. 2001;7(2):133-9.
15. Carlsson M, Bjorkman S, Berntorp E. Multidose pharmacokinetics of factor IX: implications for dosing in prophylaxis. Haemophilia. 1998;4(2):83-8.
16. Guidance for industry on population pharmacokinetics; availability. Food and Drug Administration, HHS. Notice. Fed Regist. 1999;64(27):6663-4.
17. Lindbom L, Ribbing J, Jonsson EN. Perl-speaks-NONMEM (PsN) - a Perl module for NONMEM related programming. Comput Methods Programs Biomed. 2004;75(2):85-94.
18. Jonsson EN, Karlsson MO. Xpose - an S-PLUS based population pharmacokinetic/pharmacodynamic model building aid for NONMEM. Comput Methods Programs Biomed. 1999;58(1):51-64.
19. Karlsson MO, Sheiner LB. The importance of modeling interoccasion variability in population pharmacokinetic analyses. J Pharmacokinet Biopharm. 1993;21(6):735-50.
20. Wade JR, Edholm M, Salmonson T. A guide for reporting the results of population pharmacokinetic analyses: a Swedish perspective. AAPS J. 2005;7(2):45.
21. Ette EI, Ludden TM. Population pharmacokinetic modeling: the importance of informative graphics. Pharm Res. 1995;12(12):1845-55.
22. Savic RM, Karlsson MO. Importance of shrinkage in empirical Bayes estimates for diagnostics: problems and solutions. AAPS J. 2009;11(3):558-69.
23. Xu XS, Yuan M, Karlsson MO, Dunne A, Nandy P, Vermeulen A. Shrinkage in nonlinear mixed-effects population models: quantification, influencing factors, and impact. AAPS J. 2012;14(4):927-36.
24. Sherwin CM, Kiang TK, Spigarelli MG, Ensom MH. Fundamentals of population pharmacokinetic modelling: validation methods. Clin Pharmacokinet. 2012;51(9):573-90.
25. Brendel K, Dartois C, Comets E, Lemenuel-Diot A, Laveille C, Tranchand B, et al. Are population pharmacokinetic and/or pharmacodynamic models adequately evaluated? A survey of the literature from 2002 to 2004. Clin Pharmacokinet. 2007;46(3):221-34.
26. Gui T, Lin HF, Jin DY, Hoffman M, Straight DL, Roberts HR, et al. Circulating and binding characteristics of wild-type factor IX and certain Gla domain mutants in vivo. Blood. 2002;100(1):153-8.
27. Mahmood I. Theoretical versus empirical allometry: facts behind theories and application to pharmacokinetics. J Pharm Sci. 2010;99(7):2927-33.
28. Udata C, Sullivan S, Kelly P, Roth DA, Meng X. Population pharmacokinetic modeling of BeneFIX in pediatric and adult patients with hemophilia B demonstrates weight as an important factor contributing to inter-patient PK variability. Blood. 2008;112(11):443-4.
29. Bjorkman S. Population pharmacokinetics of recombinant factor IX: implications for dose tailoring. Haemophilia. 2013;19(5):753-7.